2024
Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC.
Stein S, Cheng W, Wiess C, Pollak J, Perez Lozada J, Chapiro J, Madoff D. Atezolizumab and bevacizumab in combination with TACE for patients with BCLC B HCC. Journal Of Clinical Oncology 2024, 42: tps584-tps584. DOI: 10.1200/jco.2024.42.3_suppl.tps584.Peer-Reviewed Original ResearchRates of grade 3Grade 3Child-Pugh A cirrhosisBCLC-B HCCCombination of atezolizumabCurative intent therapyMain portal veinRisk of bleedingDiagnosis of HCCSignificant autoimmune diseaseSingle arm pilot studyB HCCECOG PSEffective regimenOpen-labelOverall survivalGastroesophageal varicesIntent therapyPredicted probabilityAutoimmune diseasesHepatic arteryPortal veinHepatic encephalopathyPatientsImprove outcomes
2003
Management of TIPS-related Refractory Hepatic Encephalopathy with Reduced Wallgraft Endoprostheses
Madoff DC, Perez-Young IV, Wallace MJ, Skolkin MD, Toombs BD. Management of TIPS-related Refractory Hepatic Encephalopathy with Reduced Wallgraft Endoprostheses. Journal Of Vascular And Interventional Radiology 2003, 14: 369-374. PMID: 12631643, DOI: 10.1097/01.rvi.0000058418.01661.48.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic shuntRefractory Hepatic EncephalopathyIntrahepatic portosystemic shuntHE recurrenceClinical improvementShunt reductionHepatic encephalopathyBalloon occlusionClinical statusPortosystemic shuntPatientsHours of reductionEndograftEndoprosthesesEncephalopathyRecurrenceShuntWeeks